Repligen Cash Flow Statement
NASDAQ: RGENHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Repligen free cash flow
In fiscal 2025, Repligen generated $117.4 million of operating cash flow and spent $23.5 million on capital expenditures. That left free cash flow of $93.9 million, a free-cash-flow margin of 12.7% of revenue. Free cash flow was down 37.3% from the prior year's $149.7 million.
Summary generated from market data by MetaCap's automated system. Methodology
Repligen cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-12-31 | FY 20242024-12-31 | FY 20232023-12-31 | FY 20222022-12-31 | FY 20212021-12-31 | FY 20202020-12-31 | FY 20192019-12-31 | FY 20182018-12-31 | FY 20172017-12-31 | FY 20162016-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | 48.89M | -25.51M | 35.60M | 185.96M | 128.29M | 59.93M | 21.41M | 16.62M | 28.35M | 11.68M |
| Net Income growth (YoY) | — | -171.68% | -80.86% | +44.95% | +114.08% | +179.88% | +28.85% | -41.39% | +142.73% | +25.00% |
| Depreciation & Amortization | 78.75M | 69.67M | 68.56M | 50.98M | 38.45M | 27.07M | 20.87M | 15.78M | 10.51M | 5.33M |
| Stock-Based Compensation | 32.60M | 48.07M | 25.57M | 27.32M | 27.50M | 17.01M | 12.85M | 10.19M | 6.75M | 4.59M |
| Change in Working Capital | -32.20M | 62.34M | 5.88M | -71.25M | -93.16M | -47.21M | -4.93M | -11.04M | -8.77M | -14.61M |
| Operating Cash Flow | 117.42M | 175.39M | 113.92M | 172.08M | 119.02M | 62.63M | 67.22M | 32.77M | 17.45M | 7.52M |
| Capital Expenditures | -23.52M | -25.68M | -36.22M | -84.83M | -67.09M | -22.45M | -18.50M | -10.63M | -5.45M | -4.33M |
| Investing Cash Flow | -298.47M | -86.38M | -123.28M | -233.24M | -221.17M | -201.38M | -205.31M | -14.04M | -98.70M | -49.19M |
| Share Repurchases | 0 | 0 | -14.39M | 0 | 0 | — | — | — | — | — |
| Financing Cash Flow | -15.21M | -82.90M | 248.96M | -13.34M | 961.00K | 305.92M | 484.87M | 3.41M | 129.94M | 112.11M |
| Net Change in Cash | -191.33M | 6.03M | 227.87M | -80.36M | -113.48M | 179.88M | 343.58M | 20.06M | 51.08M | 68.14M |
| Free Cash Flow | 93.90M | 149.72M | 77.70M | 87.25M | 51.93M | 40.17M | 48.71M | 22.14M | 12.00M | 3.20M |
This table shows 10 annual periods of Repligen's cash flow statement, from FY 2025 back to FY 2016, across 11 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow RGEN's reporting calendar. What is a cash flow statement?